Overview
| Trade Names: | Alcomicin; Apogen; Bristagen; G-Mycin; G-Myticin; Garamycin; Garamycin Otic Solution; Genoptic Liquifilm; Genoptic S.O.P.; Gentacidin; Gentafair; Gentak; Gentamar; Gentamcin Sulfate; Jenamicin; Ocu-Mycin; Spectro-Genta; U-gencin |
|---|---|
| Brand Mixtures: | Diprogen Crm (Betamethasone Dipropionate + Gentamicin Sulfate); Diprogen Ont (Betamethasone Dipropionate + Gentamicin Sulfate); Garasone Oph/Ot Sol (Betamethasone + Gentamicin Sulfate); Garasone Ophthalmic Ointment (Betamethasone + Gentamicin Sulfate); Gentamicin Sulfate in Nacl 0.9% Inj (Gentamicin Sulfate + Sodium Chloride); Gentocin Durafilm (Betamethasone 21-Acetate + Gentamicin Sulfate); Gentocin Otic Solution (Betamethasone + Gentamicin Sulfate); Otomax Ointment (Betamethasone + Clotrimazole + Gentamicin Sulfate); Sandoz Pentasone (Betamethasone + Gentamicin Sulfate); Topagen Ont (Betamethasone + Gentamicin Sulfate); Topagen Spray (Betamethasone + Gentamicin Sulfate); Valisone G Cream (Betamethasone + Gentamicin Sulfate); Valisone G Ointment (Betamethasone + Gentamicin Sulfate) |
| PharmGKB Accession Id: | PA449753 |
Description
A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation). PubChem (source: Drug Bank)
Indication
For treatment of serious infections caused by susceptible strains of the following microorganisms: <i>P. aeruginosa</i>, <i>Proteus</i> species (indole-positive and indole-negative), <i>E. coli</i>, <i>Klebsiella-Enterobactor-Serratia</i> species, <i>Citrobacter</i> species and <i>Staphylococcus</i> species (coagulase-positive and coagulase-negative). (source: Drug Bank)
ATC Therapeutic Categories
- D06AX:Other antibiotics for topical use
- J01GB:Other aminoglycosides
- S01AA:Antibiotics
- S02AA:Antiinfectives
- S03AA:Antiinfectives
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Aminoglycosides like gentamicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically gentamicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. (source: Drug Bank)
Pharmacology
Gentamicin is a broad spectrum aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses. (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Protein Binding
Low (between 0 and 30%) (source: Drug Bank)
Absorption
Injections lead to peak serum concentrations in 30-60 minutes. Topical gentamicin is readily absorbed from large burned, denuded, or granulating areas but not through intact skin. Absorption of gentamicin is faster and greater with the cream compared to the ointment. Gentamicin is absorbed in small quantities following topical application to the eye. Gentamicin is also absorbed in small amounts following topical application to the ear (especially if the eardrum is perforated or if tissue damage is present). (source: Drug Bank)
Toxicity
Mouse, intravenous LD<sub>50</sub>: 52 mg/kg; rat, intravenous LD<sub>50</sub>: 96 mg/kg. (source: Drug Bank)
Isomeric SMILES Code:
C[C@H]([C@@H]1CC[C@H]([C@@H](O1)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@H]3[C@@H]([C@H]([C@](CO3)(C)O)NC)O)N)N)N)NC (source: Drug Bank)
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
|
MT-TT |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| LRP2 |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| atracurium |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| bumetanide |
|
Increased ototoxicity (source: Drug Bank) |
| cefalotin |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefamandole |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefazolin |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefonicid |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefoperazone |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| ceforanide |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefotaxime |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefotetan |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefoxitin |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefradine |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| ceftazidime |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| ceftizoxime |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| ceftriaxone |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cefuroxime |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cephapirin |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| cisplatin |
|
Increased risk of nephrotoxicity (source: Drug Bank) |
| doxacurium |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| ethacrynic acid |
|
Increased ototoxicity (source: Drug Bank) |
| furosemide |
|
Increased ototoxicity (source: Drug Bank) |
| gallamine triethiodide |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| metocurine |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| mivacurium |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| pancuronium |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| pipecuronium |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| rocuronium |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| succinylcholine |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| thalidomide |
|
Thalidomide increases the renal toxicity of the aminoglycoside (source: Drug Bank) |
| torasemide |
|
Increased ototoxicity (source: Drug Bank) |
| tubocurarine |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
| vecuronium |
|
The agent increases the effect of muscle relaxant (source: Drug Bank) |
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
|
Ototoxicity |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
